Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

The FDA has only approved one medical wearable that provides continuous oxygen saturation ... at Masimo. The device gives medical-grade accuracy a cut above most fitness trackers, monitoring ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

One of the most helpful features on Apple Watches, blood oxygen tracking, remains MIA on watches sold after January. Here's ...

However, the jury also concluded that Masimo's current watches did not ... This noninvasive oxygen saturation measurement proved essential for at-home health monitoring, helping individuals, including ...

The trial came about due to Apple's countersuit in its ongoing legal battle with Masimo, which previously won an import ban ...

The jury agreed with Apple that Masimo’s W1 and Freedom watches and chargers willfully violated Apple’s patent rights.

Apple convinced a federal jury on Friday that early versions of health monitoring tech company Masimo's smartwatches infringe ...

In the latest lawsuit, Apple was awarded $250 in damages – the statutory minimum, which was what the company sought in its ...

This is the latest in a long battle between medical technology company Masimo and the tech giant, with Apple claiming that an ...

Artificial intelligence (AI) and other technologies have revolutionized patient monitoring ... oxygen saturation even in challenging conditions where traditional pulse oximeters may fail. Masimo ...